BioAge is a well-funded, high-risk clinical biotech where BGE-102 could become a best-in-class oral anti-inflammatory platform—or expose shareholders to binary trial downside.
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company pioneering the discovery and development of therapeutic product candidates targeting the biological mechanisms of human aging.[1, 2] The corporate mission is focused on translating key longitudinal biological findings into novel therapies to treat highly prevalent metabolic and cardiometabolic diseases.[1, 3] Currently, the company operates as a single reportable business segment dedicated to extending healthy human lifespan.[4] It does not possess any FDA-approved or commercially marketed pharmaceuticals.[5] Instead, its current revenue generation is entirely driven by upfront payments, research funding, and milestone achievements under strategic collaborations with large-scale pharmaceutical developers, most notably Novartis.[6, 7]
The primary assets and services offered by the company reside in its proprietary, machine-learning-driven discovery platform and its clinical drug candidates.[3, 8] Currently, the lead clinical asset is BGE-102, an orally available, brain-penetrant small molecule inhibitor of the NOD-like receptor protein 3 (NLRP3) inflammasome.[9] Additionally, the company is advancing oral and injectable apelin receptor (APJ) agonists as exercise mimetics to address systemic metabolic dysfunction and obesity.[3, 6, 10] Geographically, the corporate headquarters and key research operations are located in South San Francisco and Emeryville, California.[1, 8] However, its research paradigm incorporates global multi-omic data sources, including a comprehensive partnership with Age Labs AS to profile longitudinal samples from the HUNT Biobank in Norway.[11, 12]
The primary customers and strategic partners for BioAge are global biopharmaceutical corporations seeking novel, human-validated therapeutic targets to treat age-associated and metabolic disorders.[7, 13] The company's key end markets represent some of the largest therapeutic categories in global healthcare, including atherosclerotic cardiovascular disease (ASCVD), diabetic macular edema (DME), and obesity-associated metabolic syndromes.[14, 15, 16]
Strategic partners and institutional investors choose BioAge over traditional biotech peers due to its distinct, "human-first" platform.[3, 8] Unlike conventional discovery methods that initiate target identification in artificial animal models or basic cellular essays, BioAge's proprietary platform analyzes longitudinal multi-omics data collected over decades from exceptionally healthy human cohorts.[7, 17] This strategy bridges the translational gap by identifying molecular pathways pre-validated in human aging trajectories, which potentially enhances the probability of clinical development success.[13, 17]
| Corporate and Pipeline Dimensions | Detail and Strategic Scope | Source |
|---|---|---|
| Ticker / Exchange | BIOA / NasdaqGS | [4, 5] |
| Current Stage | Clinical-Stage Biopharmaceutical | [1, 2] |
| Lead Program | BGE-102 (Oral NLRP3 Inflammasome Inhibitor) | [2, 9] |
| Strategic Partners | Novartis ($550M total deal value), Eli Lilly ExploR&D | [7, 18, 19] |
| Lead Target Markets | Atherosclerotic Cardiovascular Disease (ASCVD), Diabetic Macular Edema (DME), Obesity | [3, 14, 15] |
| Data Advantage | Exclusive longevity datasets, HUNT Biobank (17,000+ longitudinal samples) | [7, 11, 12] |
The commercial success of BioAge is fundamentally linked to the clinical execution and commercial licensing of its developmental pipeline.[2, 7] The company operates a dual-pronged clinical strategy focusing on target inflammation via NLRP3 inhibition and target metabolic decline via APJ receptor agonism.[3, 6, 16]
BGE-102 is an orally available, brain-penetrant small molecule NLRP3 inhibitor discovered internally by the BioAge platform.[9] NLRP3 is an intracellular multi-protein complex that drives the maturation and secretion of highly pro-inflammatory cytokines, specifically interleukin-1 beta (IL-1β) and interleukin-6 (IL-6), which subsequently stimulate hepatic production of high-sensitivity C-reactive protein (hsCRP).[9, 20] Chronic hyperactivation of this inflammatory cascade is linked to cardiovascular events, metabolic dysfunction, and neurodegeneration.[9, 14]
BGE-102 binds to a unique molecular site, enabling it to shut down both the active and inactive states of the NLRP3 inflammasome, a structural mechanism that differentiates it from competing NLRP3 inhibitors.[21] In Phase 1 clinical studies, BGE-102 demonstrated rapid and profound reductions in systemic inflammatory markers.[6, 9] At oral doses of 60 mg and 120 mg once daily, BGE-102 achieved a median 86% reduction in hsCRP from baseline.[6, 9] Additionally, 87% to 93% of Phase 1 participants achieved normalization of hsCRP levels below the clinically critical threshold of 2 mg/L.[9]
In June 2026, BioAge initiated dosing in its Phase 2 proof-of-concept trial, QUELL-CV, to evaluate BGE-102 as a daily oral therapy in approximately 160 obese adults with elevated systemic inflammation (hsCRP > 3 mg/L) and other cardiovascular risk factors.[14] The trial is evaluating three once-daily oral doses (30 mg, 60 mg, and 90 mg) over 12 weeks to determine the optimal dose for Phase 3 development.[14] Topline results are anticipated in the second half of 2026.[14]
BioAge has also expanded the development of BGE-102 into ophthalmology.[6, 15] Hyperglycemia-induced NLRP3 activation in diabetic macular edema (DME) drives localized vascular leakage, compromise of retinal microvascular integrity, and vision loss.[15] In preclinical DME models, oral administration of BGE-102 showed near-complete protection from retinal vascular leakage.[15]
The company is initiating a Phase 1b/2a trial in DME in mid-2026, with a readout anticipated in mid-2027.[6, 15] This oral therapy aims to provide an alternative to the highly invasive and frequent intravitreal injections that represent the current standard of care for retinal diseases.[15]
The second leg of the clinical pipeline involves next-generation APJ agonists.[6, 19] The company originally developed azelaprag, an oral APJ agonist licensed from Amgen.[10, 18] However, in December 2024, the Phase 2 STRIDES study evaluating azelaprag in combination with Eli Lilly's tirzepatide (Zepbound) was halted due to safety concerns regarding asymptomatic liver transaminitis in 11 patients.[22, 23] Consequently, azelaprag was terminated in January 2025.[19, 22]
To salvage the APJ opportunity, BioAge shifted its focus to next-generation, structurally distinct APJ agonists.[6, 19] APJ is a receptor for apelin, an exercise-induced signaling molecule (exerkine) that mediates physical activity benefits.[10, 24] Agonism of APJ functions as an exercise mimetic designed to preserve lean muscle mass during intensive, incretin-driven weight loss.[10, 25]
BioAge is advancing proprietary oral small molecules and holds an exclusive option agreement with JiKang Therapeutics to license a highly potent APJ agonist antibody.[6, 11, 12] BioAge intends to submit its first Investigational New Drug (IND) application for an APJ agonist program by the end of 2026.[6]
BioAge's competitive advantage is supported by its integrated data ecosystem, structural biochemistry discoveries, and strategic partnerships [7, 8, 9]:
The addressable markets for the pipeline programs are exceptionally large, representing high-growth areas in global primary care [3, 14]:
The NLRP3 space is highly competitive, attracting significant investment from major pharmaceutical companies.[28] In early 2026, Eli Lilly acquired Ventyx Biosciences for $1.2 billion, highlighting the commercial value of once-daily oral NLRP3 therapies.[27, 29, 30]
| Competitor | Lead Asset | Clinical Stage / Indication | Comparative Position vs. BioAge | Source |
|---|---|---|---|---|
| Eli Lilly / Ventyx | VTX3232 / VTX2735 | Phase 2 / Obesity-Associated Cardiometabolic, Pericarditis | VTX3232 demonstrated a 64% hsCRP reduction in obesity trials at 12 weeks. BioAge’s BGE-102 showed an 86% median reduction in Phase 1 trials. | [9, 21, 27] |
| Novo Nordisk | Ziltivekimab | Phase 3 / Atherosclerotic CVD, Heart Failure (ZEUS and HERMES) | Ziltivekimab is a potent injectable IL-6 monoclonal antibody. BGE-102 is a daily oral small molecule designed for convenient primary care settings. | [20, 21, 31, 32] |
| NodThera | NT-0796 | Phase 2 / Obesity, Parkinson's | NT-0796 is being evaluated as monotherapy and in combination with GLP-1s. BioAge’s BGE-102 is competitively positioned as a "pipeline in a pill" covering CNS, CV, and retinal diseases. | [9, 27, 28] |
BioAge is currently holding its ground and gaining momentum.[5, 33] Although the late 2024 azelaprag clinical termination was a setback [23], the rapid clinical initiation of BGE-102 in the Phase 2 QUELL-CV trial in June 2026 has restored institutional and scientific confidence.[14, 34]
BioAge announced its financial results for the first quarter of 2026 on May 8, 2026.[6] The company’s performance highlights its transition into a late-stage clinical developer [5, 16]:
| Q1 2026 Financial Metrics | Q1 2026 ($ in thousands) | Q1 2025 ($ in thousands) | YoY Change (%) | Source |
|---|---|---|---|---|
| Collaboration Revenue | $2,772 | $1,451 | 91.04% | [35, 36] |
| Research & Development | $20,410 | $11,109 | 83.72% | [35] |
| General & Administrative | $7,737 | $6,788 | 13.98% | [35] |
| Net Loss | ($22,253) | ($12,928) | -72.13% | [35] |
| Basic & Diluted EPS (USD) | ($0.52) | ($0.36) | -44.44% | [35] |
| Cash & Equivalents | $384,900 | $335,100 (Q1 2025) | 14.86% | [6, 38] |
During the R&D Day held on May 8, 2026, CEO Kristen Fortney emphasized that the Phase 1 clinical results position BGE-102 as a potential best-in-class NLRP3 inhibitor, with the opportunity to address NLRP3-driven inflammation across cardiovascular, ocular, and CNS diseases.[9, 16] Chief Medical Officer Paul Rubin highlighted that targeting chronic systemic inflammation with a convenient oral therapeutic could provide cardiovascular benefit, similar to how statins transformed care for lipid management decades ago.[9, 14]
The Q1 2026 earnings announcement had a positive effect on institutional sentiment.[8, 39] Although the stock traded in a consolidated range between $16.00 and $18.00 in May 2026, analyst target prices remained supportive.[33, 40] Following the initiation of dosing in the Phase 2 QUELL-CV trial on June 16, 2026, the stock climbed to $25.10 by early July 2026.[4, 34, 41]
Wall Street analysts maintained an average consensus 12-month target price of $49.50, representing potential upside from the current share price.[37, 42] Analyst target prices ranged from a low of $23.00 to a high of $73.00, reflecting varying expectations for the upcoming Phase 2 clinical trial readouts.[37]
To value BioAge, standard trailing multiples are not highly informative due to its pre-commercial status.[5, 43] Valuation is primarily driven by the probability-adjusted Net Present Value (rNPV) of BGE-102 across ASCVD and DME indications [14, 15], alongside the next-generation APJ program.[6] Key financial parameters include:
BioAge has a highly concentrated clinical pipeline.[2] Following the discontinuation of azelaprag in early 2025 [19], the company's valuation is heavily dependent on BGE-102.[28] Any safety signals or a failure to meet the primary endpoint of hsCRP reduction in the Phase 2 QUELL-CV trial in late 2026 would disrupt the core investment thesis.[14, 46]
Additionally, the APJ agonist antibody program in collaboration with JiKang is early-stage, and any delays in submitting the first IND by the end of 2026 would set back development timelines.[6, 11]
The anti-inflammatory cardiometabolic market is highly active.[21, 27] Competitors like NodThera are already evaluating once-daily oral NLRP3 inhibitors (such as NT-0796) in combination with GLP-1 agonists.[27]
Furthermore, Novo Nordisk is advancing ziltivekimab in late-stage Phase 3 trials (ZEUS and HERMES), which could establish a dominant clinical position in cardiovascular inflammation management.[31, 32, 47] If these competitors establish a strong clinical footprint before BGE-102 enters Phase 3, BioAge’s market opportunity could be constrained.[21]
The company’s non-dilutive financial runway is highly dependent on partnerships with Novartis and Eli Lilly ExploR&D.[7, 19] Under the Novartis collaboration, BioAge's collaboration revenue is directly tied to the level of FTE research effort allocated to the target discovery project.[6]
If Novartis or Lilly restructures their research priorities or terminates their agreements, BioAge would lose significant milestone opportunities and experience a reduction in research funding.[7, 19]
The systemic inhibition of NLRP3, a key component of the innate immune system, carries potential regulatory risks.[9, 31] While BGE-102 has been well tolerated to date [6, 9], chronic inhibition of NLRP3 could lead to an increased rate of severe infections or localized immunosuppression.[31]
The FDA could require long-term safety studies or implement black-box warnings, which would increase clinical trial costs and delay potential commercialization.[23]
Clinical biotechnology development is highly capital-intensive.[21] Although the $384.9 million in cash provides a runway through 2029 [6], advancing BGE-102 and next-generation APJ compounds through Phase 3 trials will require substantial clinical expenditures.[6, 11, 21]
If BioAge cannot secure a co-development partner to share Phase 3 expenses, it will need to raise capital through dilutive equity offerings, reducing long-term shareholder value.[5, 45]
As a pre-commercial, clinical-stage biotechnology stock, BioAge is highly sensitive to the macroeconomic cost of capital.[40] A higher interest rate environment increases the discount rate applied to its long-dated future cash flows, compressing valuations.
Conversely, a macroeconomic environment characterized by monetary easing historically increases risk appetite for small-cap clinical biotechs, improving refinancing conditions.[40]
Risk Horizon and Actionable Framework
========================================================================================
What Could Go Wrong -> DME enrollment delays, early APJ transaminitis [6, 23]
Early Warning Signs -> Accelerating insider sales, lack of Novartis milestones [48]
Long-Term Thesis Damage -> BGE-102 failing to outperform placebo in Phase 2 [14, 46]
========================================================================================
This analysis projects three realistic outcomes for BioAge Labs, Inc. over a 5-year horizon (ending July 2031), starting from a baseline stock price of $25.10 [4, 41] and 44.39 million outstanding common shares [35, 37]:
In this scenario, BGE-102 fails to show statistically significant reductions in hsCRP compared to placebo in the Phase 2 QUELL-CV trial in late 2026 [14, 46], or it exhibits unexpected late-stage toxicities. Consequently, the DME ophthalmology expansion is halted.[6] Novartis and Eli Lilly terminate their research collaborations due to target validation failures [7, 19], causing collaboration revenues to decline to a nominal $1.0 million by 2031.
The next-generation APJ programs fail to enter the clinic.[6] To survive, the company undergoes restructuring, and dilutive share issuances to fund preclinical programs expand the outstanding share count to 80 million. The pipeline is written down, and the company is valued purely on its remaining net cash of $120 million, yielding an implied future share price of $1.50 USD, which represents a -94.0% total return.
In this scenario, BGE-102 delivers positive Phase 2 QUELL-CV data in late 2026, demonstrating best-in-class hsCRP, IL-6, and fibrinogen reductions with a favorable safety profile.[9, 14] The DME program reports positive Phase 1b/2a proof-of-concept data in mid-2027, showing clinical improvements in visual acuity.[6, 15] BioAge initiates Phase 3 trials in 2028 with co-development support.[11, 21] Concurrently, the APJ agonist antibody program successfully enters Phase 2 trials.[6]
By Year 5 (2031), collaboration and milestone revenues grow at a 30% CAGR from 2025’s $9.0M base [44], reaching approximately $33 million. More importantly, BGE-102 is valued based on its risk-adjusted peak sales potential of $800 million across ASCVD and DME indications.[14, 15] Applying an EV/Peak Sales multiple of 4.0x on risk-adjusted peak sales yields an Enterprise Value of $3.2 billion. Adding residual cash of $150 million yields a Market Capitalization of $3.35 billion. Assuming moderate dilution to 58 million outstanding shares to support Phase 3 development, the implied future share price is $57.76 USD, representing a 130.1% total return.
In this scenario, BGE-102 delivers excellent Phase 2 data, positioning it as a best-in-class oral anti-inflammatory agent with pipeline-in-a-pill potential across cardiovascular and retinal indications.[9, 14] It attracts a high-value global co-development partner, triggering large upfront cash payments and eliminating the need for dilutive equity raises.[7, 45] Concurrently, the next-generation APJ agonist antibody program demonstrates blockbuster potential in obesity trials, showing preservation of lean muscle mass when combined with GLP-1 therapies.[11, 25]
By 2031, BioAge has launched BGE-102, and its risk-adjusted peak sales are modeled at $1.5 billion.[14, 15] Applying a 5.0x peak sales multiple yields an enterprise value of $7.50 billion. Supported by milestone cash flows, the share count remains tightly managed at 50 million. The implied future stock price reaches $150.00, representing a 497.6% total return, which is aligned with the premium multiples seen in major clinical acquisitions like Ventyx ($1.2 billion clinical acquisition by Lilly).[29, 30]
| Scenario Trajectory (USD) | Year 1 (2027) | Year 2 (2028) | Year 3 (2029) | Year 4 (2030) | Year 5 (2031) | Source |
|---|---|---|---|---|---|---|
| Low Case | $10.00 | $5.00 | $3.50 | $2.00 | $1.50 | [6, 35, 41] |
| Base Case | $32.00 | $38.00 | $45.00 | $50.00 | $57.76 | [6, 35, 41] |
| High Case | $45.00 | $65.00 | $90.00 | $120.00 | $150.00 | [6, 35, 41] |
| Scenario | Year 5 Target Metric (Risk-Adj. Peak Sales) | Margin / Earnings Assumption | Valuation Multiple Assumption | Current Share Price (USD) | Implied Year 5 Share Price (USD) | 5-Year Total Return (%) | Annualized Return (%) | Subjective Probability (%) |
|---|---|---|---|---|---|---|---|---|
| Low Case | $0 Million | N/A (Liquidating/Stalled) | 1.0x cash value | $25.10 | $1.50 | -94.02% | -43.02% | 20% |
| Base Case | $800 Million | N/A (Late Phase 3) | 4.0x Peak Sales | $25.10 | $57.76 | 130.12% | 18.14% | 55% |
| High Case | $1.60 Billion | N/A (Commercial Launch) | 5.5x Peak Sales | $25.10 | $175.00 | 597.21% | 47.45% | 25% |
The probability-weighted target price is calculated as:
$\text{Weighted Price Target} = (0.20 \times \$1.50) + (0.55 \times \$57.76) + (0.25 \times \$175.00) = \$0.30 + \$31.77 + \$43.75 = \$75.82 \text{ USD}$
ASYMMETRIC METABOLIC OPTION.
| Scorecard Dimension | Score (1-10) | Key Qualitative Driver | Source |
|---|---|---|---|
| 1. Management Alignment | 6/10 | CEO owns 2.2% of stock ($23M); insider sales under 10b5-1 plans. | [49, 50] |
| 2. Revenue Quality | 4/10 | Pre-commercial; relies on non-recurring collaboration payments. | [5, 6] |
| 3. Market Position | 7/10 | Potential best-in-class oral efficacy; competes with large pharma. | [9, 27, 28] |
| 4. Growth Outlook | 8/10 | Dual-indication Phase 2 readouts for BGE-102; next-gen APJ IND. | [6, 14] |
| 5. Financial Health | 9/10 | $384.9M cash; minimal debt; operational runway through 2029. | [6, 35] |
| 6. Business Viability | 5/10 | Speculative biotech; risk of clinical termination (e.g., azelaprag). | [22, 23] |
| 7. Capital Allocation | 7/10 | Cut azelaprag quickly to preserve cash; upsized follow-on offering. | [6, 23, 45] |
| 8. Analyst Sentiment | 8/10 | Consistently bullish buy ratings; target price average of $49.50. | [37, 42] |
| 9. Profitability | 1/10 | Substantial operating losses ($22.3M in Q1 2026); pre-profit stage. | [6, 35] |
| 10. Track Record | 4/10 | Short public history (IPO Sept 2024); early azelaprag setback. | [23, 25] |
| Blended Overall Score | 5.9 / 10 | Speculative high-growth clinical-stage profiling. |
The management team displays moderate alignment with public shareholders.[49] CEO Kristen Fortney directly owns approximately 2.2% of the outstanding common stock, representing a holding value of $23.21 million.[49]
However, alignment is offset by recent insider activity.[48] In January 2026, Fortney filed an intent to sell 233,000 shares ($4.2 million) under a 10b5-1 plan [49, 50], and Principal Accounting Officer Shane Barton sold his entire direct position of 20,216 shares in June 2026.[48] Regular option grants also contribute to shareholder dilution.[6]
Revenue quality is low because the company has no commercial product sales or recurring service streams.[5] All generated revenue consists of milestone-dependent collaboration payments under the Novartis target-discovery agreement, which is linked to ongoing FTE research allocations.[6, 35]
BGE-102 is competitively positioned in the oral NLRP3 class.[9, 27] Its Phase 1 hsCRP reduction of 86% compares favorably to the 64% reduction reported by Ventyx's VTX3232.[9, 21]
However, BioAge faces deep-pocketed competitors like Novo Nordisk, which is advancing late-stage injectable anti-inflammatories.[27, 51]
The growth outlook is strong, supported by the clinical progression of BGE-102 into the Phase 2 QUELL-CV trial [14] and the Phase 1b/2a DME trial in mid-2026.[6, 15] The next-generation APJ agonist program also represents a complementary growth catalyst, with an IND filing planned by the end of 2026.[6]
Financial health is excellent, supported by $384.9 million in cash, cash equivalents, and marketable securities as of March 31, 2026.[6, 35] The debt-to-equity ratio is near-zero (0.01) [36], providing an estimated operational runway through 2029.[6, 35]
The long-term viability of the business model is speculative.[4] Because BioAge lacks a diversified portfolio, the entire company’s viability depends on BGE-102’s clinical outcomes.[28]
The discontinuation of azelaprag highlights the binary clinical risks inherent in drug development.[22, 23]
Management has demonstrated discipline in capital allocation.[23] By immediately halting the Phase 2 STRIDES study of azelaprag upon detecting liver transaminitis, the company preserved its cash reserves for BGE-102.[6, 23]
Additionally, the upsized $132.3 million follow-on equity offering in early 2026 strengthened the balance sheet ahead of the Phase 2 trials.[6, 45]
Wall Street sentiment is highly positive.[8] Out of eight analysts covering the stock, seven maintain buy recommendations.[42]
Target prices remain supportive, with a consensus target of $49.50 representing significant potential upside.[37, 42]
BioAge is unprofitable, recording a net loss of $22.25 million for Q1 2026.[35] Due to its pre-commercial stage, the company is not expected to achieve profitability over the next three years.[5]
The company has a limited public track record, having completed its IPO in late September 2024.[23, 25] The clinical termination of azelaprag shortly after the IPO disrupted initial shareholder value creation [23], though management is successfully steering a clinical recovery.
SPECULATIVE VOLATILITY PROFILE.
BioAge Labs, Inc. represents a high-potential, clinical-stage biotechnology opportunity targeting the biology of human aging.[1, 2] While the termination of azelaprag in early 2025 demonstrated the high risks of drug development [19, 23], the company's strong capital position and strategic pivot have established a clearer path forward.[6, 22] Supported by $384.9 million in cash and marketable securities [6, 35], BioAge has a cash runway through 2029 [6, 35], which limits the immediate risk of dilutive financing.
The investment thesis is driven by the clinical development of BGE-102, which is currently evaluating once-daily oral NLRP3 inhibition in the Phase 2 QUELL-CV trial.[9, 14] If BGE-102 replicates its Phase 1 anti-inflammatory efficacy (86% hsCRP reduction) with a clean safety profile in the second half of 2026, the company will be well-positioned to address a major unmet need in cardiovascular and retinal diseases.[9, 14, 15]
Conversely, any safety signals or a failure to demonstrate efficacy in the upcoming readouts would affect the company's long-term outlook.[46] Overall, BioAge’s proprietary multi-omics platform and strong balance sheet present a compelling, high-risk asymmetric opportunity in metabolic and inflammatory disease management.[3, 8, 35]
HIGH-CONVIVIAL CLINICAL CATALYSTS.
As of July 2, 2026, BioAge trades at $25.10, representing an 89.7% year-to-date gain and reflecting positive price action following the start of patient dosing in the Phase 2 QUELL-CV trial.[4, 34, 41] Technically, the stock is trading in an uptrend, holding above both its 50-day moving average of $18.50 and its 200-day moving average.[40, 43, 44] Trading volume has normalized, and near-term resistance is established around $25.80, with support holding near $16.43.[4, 33, 37] The options market exhibits high implied volatility (88.6), suggesting that the stock is consolidating in a neutral-to-bullish pattern ahead of the key Phase 2 topline readouts in the second half of 2026.[14, 43]
UPTREND AWAITING READOUT.
View BioAge Labs, Inc. (BIOA) stock page
Loading the interactive version of this report…